MOSCOW: Siberia’s Vector virology institute on Tuesday completed early-stage human trials, known as Phase II, of a second potential Russian vaccine against COVID-19, the state consumer safety watchdog was cited by the Interfax news agency as saying.
Russia registered its first vaccine candidate, developed by Moscow’s Gamaleya Institute, in August after completing early-stage human trials.
“Today… the final group of 20 volunteers was released from hospital,” watchdog Rospotrebnadzor said in a statement.
“All 100 volunteers were vaccinated with two doses and have completed a 23-day monitoring period in hospital. The volunteers are feeling good.”
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor
Comments
0 comment